Combined modality treatment with ABI-007, nanoparticle albumin-bound (nab) paclitaxel:: modification of radiation response in vivo

被引：0
|
作者：
Wiedenmann, N. [1 ,2 ]
Valdecanas, D. [2 ]
Hunter, N. [2 ]
Farrar, D. [2 ]
Milas, L. [2 ]
Mason, K. [2 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Strahlentherapie & Radiol Onkol, D-8000 Munich, Germany
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2007年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A13
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] In vivo radiation enhancement by ABI-007, a nanoparticle albumin-bound (nab) paclitaxel
    Wiedenmann, N.
    Valdecanas, D.
    Farrar, D.
    Milas, L.
    Mason, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 13 - 14
  • [2] ABI-007, nanoparticle albumin-bound paclitaxel, enhances tumor radioresponse.
    Mason, Kathy A.
    Wiedenmann, Nicole
    Valdecanas, David
    Buchholz, Thomas
    Milas, Luka
    CANCER RESEARCH, 2006, 66 (08)
  • [3] SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane)
    Trieu, Vuong
    Damascelli, Bruno
    Soon-Shiong, Patrick
    Desai, Neil
    CANCER RESEARCH, 2006, 66 (08)
  • [4] Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
    Miele, Evelina
    Spinelli, Gian Paolo
    Miele, Ermanno
    Tomao, Federica
    Tomao, Silverio
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2009, 4 (01): : 99 - 105
  • [5] Radiosensitizing effects of ABI-007, a novel solvent-free nanoparticle albumin-bound (NAB) paclitaxel: Preclinical studies on tumor and normal tissue models
    Wiedenmann, N.
    Valdecanas, D.
    Hunter, N.
    Farrar, D.
    Milas, L.
    Mason, K. A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 65 - 66
  • [6] Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma
    Altundag, Kadri
    Dede, Didem S.
    Purnak, Tugrul
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (08) : 958 - 958
  • [7] Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
    Sparreboom, A
    Scripture, CD
    Trieu, V
    Williams, PJ
    De, TP
    Yang, A
    Beals, B
    Figg, WD
    Hawkins, M
    Desai, N
    CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4136 - 4143
  • [8] Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies
    Lee, C. B.
    Stinchcombe, T. E.
    Socinski, M. A.
    Hayes, D. N.
    Goldberg, R. M.
    Hawkins, M. J.
    Obasaju, C. K.
    Dees, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    Ibrahim, NK
    Samuels, B
    Page, R
    Doval, D
    Patel, KM
    Rao, SC
    Nair, MK
    Bhar, P
    Desai, N
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6019 - 6026
  • [10] Automated quantitative analysis of AKT/mTOR pathway in patients treated with nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) and (sirolimus) Rapamycin
    Abu-Khalaf, M. M.
    Moeder, C.
    Gettinger, S.
    Rimm, D.
    Harris, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345